The Top Line

The Top Line

By Fierce Life SciencesNewsBusiness News
Download on the App Store

The Top Line episodes

  • Why modern clinical trials need a finance-first strategy (Sponsored)

    Clinical trial success depends on more than scientific rigor and operational execution. It also depends on the financial systems that support every stage of a study. In this episode of The Top Line, Zahiah “Zee Zee” Gueddar, senior director of commercial strategy for the Clinical Trial Financial Suite at IQVIA Technologies, discusses why modernizing clinical trial finance has become a strategic priority for sponsors.

    As trials become more complex, fragmented systems and manual workflows are creating bottlenecks that limit visibility, delay payments and introduce unnecessary risk. Gueddar explains how these challenges affect site relationships, operational efficiency and study performance, and why organizations can no longer afford to treat finance as a disconnected administrative process.

    The conversation also highlights key indicators of readiness for transformation, from cross-functional alignment to executive sponsorship, and outlines the common pain points study teams face today. Ultimately, success depends on moving toward a connected, transparent and predictable financial model that reduces friction, improves collaboration and supports faster, more reliable clinical trials.

    See omnystudio.com/listener for privacy information.

    18 min
  • 5 emerging biotech hubs

    Boston. San Francisco. Beijing? The global biotech industry has long been concentrated in a handful of cities. But which emerging hubs could become dominant forces in biotech in the decades ahead?

    In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia and Will Maddox discuss a new Fierce special report identifying five cities with the potential to become major forces in the global biotech industry. Did your favorite city make the cut? Listen to find out. 

    To learn more about the topics in this episode: 

    • Top emerging biotech hubs in 2026 

    • As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’ 

    • British biotech VC funding shows ‘signs of recovery,’ but IPO rebound yet to materialize 

    • Could Basel be the next Boston? How the Swiss biotech hub is quietly raising its game 

    This week's episode is sponsored by IQVIA Biotech.

     
    Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit IQVIABiotech.com

    See omnystudio.com/listener for privacy information.

    25 min
  • Operating at the speed of science: The new medical affairs playbook (Sponsored)

    Medical affairs is at an inflection point. As science advances and healthcare professionals gain access to information in real time, medical teams face a mandate to deliver insight with greater speed, relevance and impact.

    In this episode of The Top Line, Josh Schwartz, Vice President of Medical Affairs, North America at BeOne Medicines, and Jalpa Shah, who leads the medical and evidence practice at ZS Pharma discuss what a modern medical affairs model requires. The conversation explores how the function is becoming a more strategic business driver and why traditional measures of activity are no longer enough to demonstrate value.

    The episode examines the structural challenges that continue to hold organizations back, including fragmented data systems, limited visibility into insights and the difficulty of translating engagement into measurable outcomes. It also looks at how artificial intelligence (AI) is reshaping workflows by helping teams generate insights faster, identify trends and inform next best actions.

    The discussion also considers the capabilities, operating models and cultural shifts medical affairs teams will need to keep pace with science and influence clinical practice. The central takeaway is clear: Future success will depend less on access to more data and more on the ability to turn intelligence into coordinated action.

    See omnystudio.com/listener for privacy information.

    23 min
  • Decision readiness is the next AI advantage (Sponsored)

    AI is reshaping how organizations compete, but more data and more tools do not automatically lead to better decisions. In this episode of The Top Line, Justin Masterson, senior vice president of human sciences at The Directions Group, challenges leaders to look beyond AI adoption and focus on the discipline required to act on intelligence.

    Masterson argues that the defining issue for many organizations is not a data problem, but a decision readiness problem. As information ecosystems become more complex, the ability to translate insight into timely, confident action is emerging as a critical business differentiator.

    With more than 20 years of experience in healthcare and human sciences, Masterson shares perspective on how companies can align teams, processes and strategies to unlock AI’s value without becoming overwhelmed by the volume of available information.

    For leaders navigating new technologies, competing priorities and higher expectations for speed, this conversation offers a practical reframing of where AI value is created. Learn why decision readiness may be the next true advantage.

    See omnystudio.com/listener for privacy information.

    19 min
  • A $10B deal, China trial scrutiny and highlights from ADA 2026

    This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer.

    First, we discuss Vertex’s $10 billion acquisition of Crinetics Pharmaceuticals, the company’s largest deal to date, and what it says about Vertex’s push beyond its historic strength in cystic fibrosis. We also cover growing scrutiny from U.S. lawmakers over the industry’s use of clinical trials in China.

    Then, Fierce Pharma Senior Editor Fraiser Kansteiner recounts his recent trip to New Orleans for the American Diabetes Association’s 2026 Scientific Sessions with Fierce Pharma Marketing’s Zoey Becker. For years, ADA has focused heavily on its eponymous indication, but this year’s meeting made clear how much the conversation is evolving, with obesity data from drugmakers of all stripes taking up more of the spotlight. Topics include the biggest data sets from the meeting, what it was like to sit down with Novo Nordisk’s new CEO for the first time and the latest from Insulet’s Marvel collaboration on a line of comics about an Omnipod-wearing superheroine.

    To learn more about the topics in this episode: 

    • Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B
    • As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’
    • ‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO
    • ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes
    • ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigree
    • With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race
    • ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone
    • ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect
    • ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update
    • ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes

    This week's episode is sponsored by IQVIA Biotech.

     
    Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit IQVIABiotech.com

    See omnystudio.com/listener for privacy information.

    25 min
  • The deal before the deal

    Big Pharma dealmaking has picked up, but the biotech path to a signed agreement is still anything but simple.

    In this episode, recorded at Fierce Biotech Week, Senior Editor James Waldron leads a discussion on the evolving BD&L landscape across pharma and biotech.

    He is joined by Kaleem Chowdhury, Ph.D., CEO of Haiku Biosciences; Liz Leveille, who leads the Boston Innovation Hub and discovery transactions at Merck; and Abbas Kazemi, CEO of Nimbus Therapeutics.

    The panel digs into the realities behind the headlines, from investor scrutiny and platform company pressure to China’s growing role in licensing and the long relationship-building that often happens before a deal gets done.

    To learn more about the topics in this episode: 

    • March M&A surge triggers high expectations for 2026
    • 'Biopharma ecosystem is back to full health,' fueled by M&A: PwC
    • Facing mounting China licensing costs, biopharma buyers turn to AI and local know-how to keep up
    • After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst
    • Was Big Pharma’s ‘unusually aggressive’ M&A spree to blame for March IPO drought?

    This week's episode is sponsored by IQVIA Biotech.

     
    Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit IQVIABiotech.com

    See omnystudio.com/listener for privacy information.

    42 min
  • FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development (Sponsored)

    In this sponsored episode of The Top Line, host Stephanie Butler is joined by Sheila Plant, vice president of regulatory affairs at Allucent, to examine how FDA Breakthrough Therapy and RMAT designations can support more strategic oncology development. 

    Although both pathways are intended to speed development, they are not interchangeable. Plant outlines the key distinctions, noting that Breakthrough Therapy requires evidence of substantial improvement over existing treatments, while RMAT is available for regenerative medicine therapies and centers on preliminary clinical evidence indicating the potential to address unmet medical needs. 

    The conversation also explores the strategic choices that determine whether sponsors are ready to pursue these designations, from building a credible data package to designing trials with clinically meaningful endpoints and keeping manufacturing readiness aligned with development timelines. 

    Once a designation is granted, closer collaboration with the FDA can help sponsors navigate development with more dynamic feedback. But as Plant emphasizes, these pathways deliver the greatest value when they are part of a disciplined regulatory strategy. 

    Listen now to learn how sponsors can approach expedited pathways with greater clarity and position oncology programs for meaningful acceleration. 

     

    See omnystudio.com/listener for privacy information.

    21 min
  • Ipsen R&D chief on pipeline discipline, partnerships and 2026 milestones

    In this episode of “The Top Line,” recorded on site at Fierce Biotech Week in Boston, Fierce’s Ayla Ellison sits down with Christelle Huguet, Ph.D., executive vice president and head of R&D at Ipsen, to discuss how the company is building its pipeline through external innovation while maintaining internal scientific accountability.

    Huguet explains Ipsen’s approach to partnering, describing the company as an “accelerator” that helps move promising science from academic labs and biotech partners toward patients. She also discusses how Ipsen evaluates which programs move forward, why transparency with partners is essential from the start and what the company is watching as it heads into a year with several key clinical and regulatory milestones.

    To learn more about the topics in this episode: 

    • Ipsen unveils data for Botox rival that drove long-acting anti-wrinkle jab into phase 3
    • Ipsen scuttles liver disease candidates from $952M Albireo acquisition

    This week's episode is sponsored by IQVIA Biotech.

     
    Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit IQVIABiotech.com

     

    See omnystudio.com/listener for privacy information.

    16 min
  • Why MRD is becoming central to oncology drug development (Sponsored)

    In this sponsored episode of The Top Line, experts from Myriad Genetics join host Stephanie Butler to examine how tumor-informed molecular residual disease, or MRD, testing is beginning to redefine what early insight can mean in oncology drug development. As biomarker-driven therapies become more precise, the ability to understand response earlier and more clearly is increasingly being viewed as foundational to smarter development strategy.

    The discussion looks at how ultrasensitive, tumor-informed MRD assays can help track response over time, potentially surface deeper signals earlier and inform decisions that shape trial design, patient selection and regulatory direction. It also considers why these capabilities may become more important as oncology programs face growing pressure to balance speed, flexibility and evidence generation.

    Listeners will hear why early diagnostic strategy is increasingly seen as a competitive differentiator, how MRD can help teams make better decisions sooner and why its role in oncology development is expected to continue to evolve and expand.

    See omnystudio.com/listener for privacy information.

    19 min
  • Behind the headlines of ASCO 2026

    Each year, the global oncology community flocks to Chicago to convene at the American Society of Clinical Oncology’s annual meeting for a weekend of buzzy data drops, practice-changing posters and insightful sessions.  

    In this week’s episode of "The Top Line," Fierce Biotech and Fierce Pharma’s Darren Incorvaia, Zoey Becker and Angus Liu break down the biggest takeaways from their weekend of reporting live from the Windy City. From “nutty” in vivo CAR-T data to a historic first for a Chinese biotech asset, ASCO 2026 reflected new and continuing trends within the evolving state of cancer care today.  

    To learn more about the topics in this episode:  

    • ASCO: Revolution Medicines confident in RAS leadership as rivals square up 

    • ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout 

    • ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary 

    This week's episode is sponsored by IQVIA Biotech.

    Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit IQVIABiotech.com

     

    See omnystudio.com/listener for privacy information.

    30 min

About The Top Line

From the publisher's feed

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's…

More shows like The Top Line

Motley Fool Hidden Gems Investing by The Motley Fool

Motley Fool Hidden Gems Investing

3,160 Listeners

WSJ Your Money Briefing by The Wall Street Journal

WSJ Your Money Briefing

1,703 Listeners

WSJ What’s News by The Wall Street Journal

WSJ What’s News

4,349 Listeners

Masters in Business by Bloomberg

Masters in Business

2,167 Listeners

The McKinsey Podcast by McKinsey & Company

The McKinsey Podcast

382 Listeners

Odd Lots by Bloomberg

Odd Lots

2,125 Listeners

Stephanomics by Bloomberg

Stephanomics

349 Listeners

WSJ Tech News Briefing by The Wall Street Journal

WSJ Tech News Briefing

1,635 Listeners

HBR IdeaCast by Harvard Business Review

HBR IdeaCast

132 Listeners

FT Tech Tonic by Financial Times

FT Tech Tonic

102 Listeners

Masters of Scale by WaitWhat

Masters of Scale

3,982 Listeners

Bold Names by The Wall Street Journal

Bold Names

1,426 Listeners

The Readout Loud by STAT

The Readout Loud

338 Listeners

BioCentury This Week by BioCentury

BioCentury This Week

33 Listeners

HBR On Leadership by Harvard Business Review

HBR On Leadership

155 Listeners